CBU
PTCT icon

CIBC Bancorp USA’s PTC Therapeutics PTCT Stock Holding History

CIBC Bancorp USA’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$378K Buy
4,640
+639
+16% +$46.1K ﹤0.01% 1416
2026
Q1 		$273K Buy
+4,001
New +$283K ﹤0.01% 1464
2025
Q3 		$508K Buy
+8,285
New +$432K ﹤0.01% 866

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

CIBC Bancorp USA's PTCT Position: Q2 2026 in Review

CIBC Bancorp USA increased its PTC Therapeutics (PTCT) stake by 16% in Q2 2026, buying an estimated $46.1K and bringing the position to 4,640 shares worth $378K. The position accounts for ﹤0.01% of the portfolio, ranked #1416.

CIBC Bancorp USA first reported a position in PTCT in Q3 2025 and has held it in 3 quarters since. The position peaked at $508K in Q3 2025. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • CIBC Bancorp USA held 4,640 shares of PTC Therapeutics worth $378K as of Q2 2026.
  • CIBC Bancorp USA bought 639 PTC Therapeutics shares in Q2 2026, an estimated $46.1K.
  • PTC Therapeutics made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q2 2026, its #1416 holding.
  • CIBC Bancorp USA first reported a position in PTC Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • CIBC Bancorp USA's PTC Therapeutics position peaked at $508K in Q3 2025.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on CIBC Bancorp USA's 13F filing for Q2 2026, filed 13 Aug 2026.